D-1454-2019 Class III Terminated

Recalled by InvaGen Pharmaceuticals, Inc. — Central Islip, NY

FDA drug recall D-1454-2019 was initiated by InvaGen Pharmaceuticals, Inc. on Jun 12, 2019 and is designated Class III. Reason for recall: Defective Container; actuator may improperly function and affect dose delivery. The recall status is terminated (terminated Jan 28, 2021). Affected quantity: 1776 bottles.

Recall Details

Product Type
Drugs
Report Date
Jul 10, 2019
Initiation Date
Jun 12, 2019
Termination Date
Jan 28, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1776 bottles

Product Description

Testosterone Topical Solution 30mg of testosterone per pump actuation * each actuation delivers 1.5 mL of solution Total contents: 110 mL to deliver 90 mL, Manufactured by: Cipla Ltd, Verna Goa, India Manufactured for: Cipla USA, Inc., Sunrise, FL 33323 NDC 69097-363-44

Reason for Recall

Defective Container; actuator may improperly function and affect dose delivery.

Distribution Pattern

Nationwide

Code Information

Lot GH80480 and GH80481, exp 3/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1454-2019
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1454-2019. Report a data issue: hello@regdatalab.com.